JP7503851B2 - Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 - Google Patents

Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 Download PDF

Info

Publication number
JP7503851B2
JP7503851B2 JP2021565854A JP2021565854A JP7503851B2 JP 7503851 B2 JP7503851 B2 JP 7503851B2 JP 2021565854 A JP2021565854 A JP 2021565854A JP 2021565854 A JP2021565854 A JP 2021565854A JP 7503851 B2 JP7503851 B2 JP 7503851B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
hpk1
alkoxy
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021565854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531446A5 (https=
JP2022531446A (ja
Inventor
ジン，ジェン
ブラコフ，スティーブン
カニシカン，エイチ．ウミット
サワスディコソル，サンサナ
チェン，ヒ
ブロディ，ジョシュア
バルドワージ，ニナ
Original Assignee
アイカーン スクール オブ メディスン アット マウント シナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディスン アット マウント シナイ filed Critical アイカーン スクール オブ メディスン アット マウント シナイ
Publication of JP2022531446A publication Critical patent/JP2022531446A/ja
Publication of JP2022531446A5 publication Critical patent/JP2022531446A5/ja
Priority to JP2024090345A priority Critical patent/JP2024113032A/ja
Application granted granted Critical
Publication of JP7503851B2 publication Critical patent/JP7503851B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021565854A 2019-05-06 2020-05-05 Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 Active JP7503851B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024090345A JP2024113032A (ja) 2019-05-06 2024-06-04 Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843816P 2019-05-06 2019-05-06
US62/843,816 2019-05-06
PCT/US2020/031527 WO2020227325A1 (en) 2019-05-06 2020-05-05 Heterobifunctional compounds as degraders of hpk1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090345A Division JP2024113032A (ja) 2019-05-06 2024-06-04 Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物

Publications (3)

Publication Number Publication Date
JP2022531446A JP2022531446A (ja) 2022-07-06
JP2022531446A5 JP2022531446A5 (https=) 2023-05-15
JP7503851B2 true JP7503851B2 (ja) 2024-06-21

Family

ID=73051660

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021565854A Active JP7503851B2 (ja) 2019-05-06 2020-05-05 Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
JP2024090345A Pending JP2024113032A (ja) 2019-05-06 2024-06-04 Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024090345A Pending JP2024113032A (ja) 2019-05-06 2024-06-04 Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物

Country Status (6)

Country Link
US (2) US12465648B2 (https=)
EP (2) EP4524137A3 (https=)
JP (2) JP7503851B2 (https=)
CN (2) CN118908962A (https=)
CA (1) CA3137916A1 (https=)
WO (1) WO2020227325A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
EP3810145A4 (en) 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TWI848141B (zh) * 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
US12459958B2 (en) 2019-07-17 2025-11-04 Beone Medicines I Gmbh Tricyclic compounds as HPK1 inhibitor and the use thereof
US11739101B2 (en) * 2020-05-06 2023-08-29 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022199652A1 (en) * 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
TW202321239A (zh) 2021-07-20 2023-06-01 瑞典商阿斯特捷利康公司 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
JP2024528722A (ja) * 2021-07-30 2024-07-30 ベイジーン リミテッド ＨＰＫ１分解誘導薬としてのピロロ［２，３－ｂ］ピラジン系の二官能性化合物及びその使用
WO2023023941A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same
AR127625A1 (es) 2021-11-10 2024-02-14 Nurix Therapeutics Inc Degradadores bifuncionales inhibidores de la quinasa del progenitor hematopoyético y usos terapeuticos de los mismos
AU2022398484A1 (en) * 2021-11-23 2024-06-13 Cullinan Oncology, Inc. Heterobifunctional compounds as hpk1 degraders
JP2025502358A (ja) * 2022-01-12 2025-01-24 シェンゼン イオノヴァ ライフ サイエンス カンパニー リミテッド Ｈｐｋ１阻害剤としてのヘテロアリール化合物およびその使用方法
WO2023151559A1 (zh) * 2022-02-08 2023-08-17 和径医药科技（上海）有限公司 杂环化合物、包含其的药物组合物及其抗肿瘤应用
CN119233974A (zh) * 2022-07-22 2024-12-31 康百达（四川）生物医药科技有限公司 一种吲哚酮衍生物及其应用
CN119604510A (zh) * 2022-08-05 2025-03-11 杭州中美华东制药有限公司 一种protac嵌合化合物及其制备方法和用途
TW202440581A (zh) * 2022-12-16 2024-10-16 中國大陸商杭州中美華東製藥有限公司 Protac嵌合化合物及其製備方法和用途
WO2024188282A1 (zh) * 2023-03-14 2024-09-19 康百达（四川）生物医药科技有限公司 吲哚酮衍生物及其在医药上的应用
CN116444495B (zh) * 2023-04-21 2025-05-13 南京中医药大学 一类吲哚酮类flt3蛋白降解剂、其制备方法及其医药用途
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN120058709A (zh) * 2023-11-28 2025-05-30 杭州和正医药有限公司 一种多芳基类衍生物及其用途
WO2025163390A2 (en) * 2024-01-29 2025-08-07 Merck Patent Gmbh Heterobifunctional compounds for the degradation of hpk1
WO2025256556A1 (zh) * 2024-06-12 2025-12-18 杭州中美华东制药有限公司 Protac嵌合化合物的固体形式、其制备方法、药物组合物和用途
WO2025256555A1 (zh) * 2024-06-12 2025-12-18 杭州中美华东制药有限公司 Protac嵌合化合物及其合成中间体的制备方法
WO2025256557A1 (zh) * 2024-06-12 2025-12-18 杭州中美华东制药有限公司 Protac嵌合化合物的药学上可接受的盐及其结晶形式、其制备方法、药物组合物和用途
CN119613482A (zh) * 2024-12-09 2025-03-14 中国药科大学 具有端氨基结构的化合物及其制备方法、药物组合物和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523340A (ja) 2000-02-15 2003-08-05 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
WO2018144649A1 (en) 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP2018531983A (ja) 2015-11-02 2018-11-01 イエール ユニバーシティ タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
JP2021511342A (ja) 2018-01-22 2021-05-06 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 癌処置のためのｂｃｌ−２タンパク質分解剤
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691147A (en) 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
ATE523499T1 (de) 2006-07-06 2011-09-15 Array Biopharma Inc Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
CL2007002670A1 (es) 2006-09-15 2008-05-16 Celgene Corp Soc Organizada Ba Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
WO2008109104A1 (en) 2007-03-07 2008-09-12 The Regents Of The University Of California Bivalent inhibitors of akt protein kinase
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
WO2009006567A2 (en) 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009134418A2 (en) 2008-04-30 2009-11-05 Fox Chase Cancer Center Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
WO2011159685A2 (en) 2010-06-16 2011-12-22 The Regents Of The University Of Michigan Inhibition of wdr5 interaction with its binding partners and therapeutic methods
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2013170147A1 (en) 2012-05-11 2013-11-14 Yale University Compounds useful for promoting protein degradation and methods using same
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
EP3083602A1 (en) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
US9796701B2 (en) 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
WO2015104677A1 (en) 2014-01-10 2015-07-16 Piramal Enterprises Limited Heterocyclic compounds as ezh2 inhibitors
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
CN106573073B (zh) 2014-06-13 2021-09-28 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016073956A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
WO2016089883A1 (en) 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016106518A1 (zh) 2014-12-29 2016-07-07 深圳市日上光电股份有限公司 导线集成式照明灯箱
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
WO2016115480A1 (en) 2015-01-16 2016-07-21 Vedantra Pharmaceuticals, Inc. Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
CN108137593B (zh) 2015-04-21 2021-01-05 上海交通大学医学院附属瑞金医院 蛋白激酶抑制剂的制备和用途
WO2016174130A1 (en) 2015-04-28 2016-11-03 Université De Strasbourg Clinical gene signature-based human cell culture model and uses thereof
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
MX2017016325A (es) 2015-06-22 2018-03-02 Ono Pharmaceutical Co Compuesto inhibidor de cinasa de tumor de mama (brk).
CN105085620B (zh) 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
CN105175284B (zh) 2015-07-21 2017-06-16 中国药科大学 酰胺类化合物、制备方法及其医药用途
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US20170114098A1 (en) 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
US11319299B2 (en) 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
JP2019507179A (ja) 2016-03-01 2019-03-14 プロペロン セラピューティックス インコーポレイテッド Ｗｄｒ５タンパク質−タンパク質結合の阻害剤
EP3445765A4 (en) 2016-04-22 2019-09-18 Dana Farber Cancer Institute, Inc. DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
EP3454856B1 (en) * 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN115819417A (zh) * 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US20180072741A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US10160763B2 (en) 2016-09-13 2018-12-25 Vanderbilt University WDR5 inhibitors and modulators
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
ES2909234T3 (es) 2016-12-21 2022-05-05 Ono Pharmaceutical Co Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
US20210283261A1 (en) 2017-12-05 2021-09-16 Icahn School Of Medicine At Mount Sinai Compositions and Methods for Treating ALK-Mediated Cancer
CA3091041A1 (en) 2018-02-22 2019-08-29 Ichan School Of Medicine At Mount Sinai Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
EP3793523B8 (en) 2018-05-15 2026-01-21 The United States of America, as represented by the Secretary, Department of Health and Human Services Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
EP3810145A4 (en) 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
CA3105121A1 (en) 2018-07-05 2020-01-09 Icahn School Of Medicine At Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
JP7706210B2 (ja) 2019-06-10 2025-07-11 ストロ バイオファーマ インコーポレーテッド ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート
WO2021021904A1 (en) 2019-07-30 2021-02-04 The Scripps Research Institute Pharmacological inhibitors of the enl yeats domain
CN112552293A (zh) 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
US11739101B2 (en) 2020-05-06 2023-08-29 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
WO2022086937A1 (en) 2020-10-21 2022-04-28 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of enl
CN112778303A (zh) 2020-12-31 2021-05-11 武汉九州钰民医药科技有限公司 Cdk4/6激酶抑制剂shr6390的制备方法
JP2024528722A (ja) 2021-07-30 2024-07-30 ベイジーン リミテッド ＨＰＫ１分解誘導薬としてのピロロ［２，３－ｂ］ピラジン系の二官能性化合物及びその使用
AU2022398484A1 (en) 2021-11-23 2024-06-13 Cullinan Oncology, Inc. Heterobifunctional compounds as hpk1 degraders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523340A (ja) 2000-02-15 2003-08-05 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
JP2018531983A (ja) 2015-11-02 2018-11-01 イエール ユニバーシティ タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
WO2018144649A1 (en) 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP2021511342A (ja) 2018-01-22 2021-05-06 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 癌処置のためのｂｃｌ−２タンパク質分解剤
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mazen W Karaman, Sanna Herrgard, Daniel K Treiber, Paul Gallant, Corey E Atteridge, Brian T Campbell, Katrina W Chan, Pietro Ciceri, Mindy I Davis, Philip T Edeen, Raffaella Faraoni, Mark Floyd, Jeremy P Hunt, Daniel J Lockhart, Zdravko V Milanov, Michael J Morrison, Gabriel Pallares, Hitesh K Patel, Stephanie Pritchard, Lisa M Wodicka and Patrick P Zarrinkar，A quantitative analysis of kinase inhibitor selectivity，nature biotechnology，UK，Nature Publishing Group，2008年01月08日，26(1)，127-132

Also Published As

Publication number Publication date
CN114423463B (zh) 2025-09-26
JP2024113032A (ja) 2024-08-21
US12465648B2 (en) 2025-11-11
CN114423463A (zh) 2022-04-29
EP3965824C0 (en) 2025-01-08
EP3965824A1 (en) 2022-03-16
EP3965824A4 (en) 2023-01-25
US20260115297A1 (en) 2026-04-30
CA3137916A1 (en) 2020-11-12
JP2022531446A (ja) 2022-07-06
EP4524137A3 (en) 2025-04-30
EP4524137A2 (en) 2025-03-19
CN118908962A (zh) 2024-11-08
EP3965824B1 (en) 2025-01-08
US20230022524A1 (en) 2023-01-26
WO2020227325A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
JP7503851B2 (ja) Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
CN109963842B (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
JP2025528128A (ja) 複素環式化合物、その組成物、及びそれを用いた処置の方法
KR20210069634A (ko) 트로포미오신 수용체 키나아제(trk) 분해 화합물 및 사용 방법
KR20210025061A (ko) 세레블론(crbn)에 대한 리간드
JP2021527666A (ja) Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
BR112014030655B1 (pt) compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
AU2016214492B2 (en) 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity
US11008318B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
JP2021529807A (ja) タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法
EP4519260A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xdegraders
JP2025528766A (ja) Ｈｅｒ２を調節するための化合物および方法
WO2023097020A1 (en) Heterobifunctional compounds as hpk1 degraders
TW202448898A (zh) 用於egfr激酶降解之化合物
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
US11660303B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
HK40070738A (en) Heterobifunctional compounds as degraders of hpk1
HK40070738B (en) Heterobifunctional compounds as degraders of hpk1
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2025221930A1 (en) Cbp/p300 heterobifunctional conditional inhibitors
IL319211A (en) Triazine compounds and their uses
HK40003421A (en) Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof
HK40003421B (en) Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240604

R150 Certificate of patent or registration of utility model

Ref document number: 7503851

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150